“Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients With Metabolic Syndrome”. Journal of Carcinogenesis 24, no. 3s (September 12, 2025): 441–448. Accessed December 6, 2025. https://carcinogenesis.com/index.php/JOC/article/view/761.